Viral 2A-peptides mediate continuous transcription and self-cleavage of multiple heterologous genes in fowlpox virus vector

RANJANI RAJASEKARAN; J JOHN KIRUBAHARAN; P SHILPA; M VIDHYA; S RAJALAKSHMI

doi:10.56093/ijans.v90i9.109445

Authors

RANJANI RAJASEKARAN Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University
J JOHN KIRUBAHARAN Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University
P SHILPA Veterinary Dispensary, Vilayur, Palakkad
M VIDHYA Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu 600 007 India
S RAJALAKSHMI Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu 600 007 India

https://doi.org/10.56093/ijans.v90i9.109445

Keywords:

Co-expression, Multi-cistronic transcription, Plasmid, Recombinant fowlpox virus, Self-cleaved protein, Viral 2A-peptide

Abstract

Applicability of viral 2A-peptides in generation of multi-cistronic transcripts to deliver separate self-cleaved proteins is well established. However, the use of viral 2A-peptides in fowlpox virus vector construction to co-express multiple heterologous genes has not been explored. To evaluate the same, a recombinant transfer plasmid pJFWPVt was constructed through two intermediate plasmid constructs, pJF7F9 and pJFHNGFP. The construction of pJF7F9 involved cloning of F7 and F9 genes of FWPV into pCI-neo with modifications in the F7-F9 intergenic region. For the construction of pJFHNGFP, a synthetic DNA adapter consisting of one synthetic early late promoter (PE/L), two viral 2A-peptides (P2A and T2A) and three multiple cloning sites (MCS1, MCS2 and MCS3) was synthesized chemically and was cloned into pUC19 to obtain pJFHNGFPi. Heterologous genes fusion (F) and haemagglutininneuraminidase (HN) of Avian Avulavirus-1 (AAv1) and marker gene AcGFP were cloned sequentially into MCS1, MCS2 and MCS3 of pJFHNGFPi to obtain pJFHNGFP. The insert (PE/L-F-P2A-HN-T2A-AcGFP) in pJFHNGFP was cloned into pJF7F9 to obtain pJFWPVt, which upon transfection in FWPV infected chicken embryo fibroblast (CEF) cells resulted in fluorescence. This confirmed the expression of AcGFP and the continuous transcription ability of viral 2A-peptides. Further, western blotting of CEF pellet showed separate protein bands of F and HN protein at 66 kDa and 74 kDa respectively, which confirmed the self-cleaving ability of viral 2A-peptides. Herein, in FWPV vector construction, continuous transcription and self-cleaving ability of viral 2A-peptides in FWPV vector construction was confirmed. This warrants scope for future viral 2A-peptide based FWPV vector construction.

Downloads

Download data is not yet available.

References

1. Ball L A. 1987. High-frequency homologous recombination in Vaccinia virus DNA. Journal of Virology 61: 1788–95. DOI: https://doi.org/10.1128/jvi.61.6.1788-1795.1987

2. Bond S R and Naus C C. 2012. RF-Cloning.org: An online tool for the design of restriction-free cloning projects. Nucleic Acids Research 40: W209–W213. DOI: https://doi.org/10.1093/nar/gks396

3. Boyle D B, Anderson M A A, Amos R, Voysey R and Coupar B E H H. 2004. Construction of recombinant Fowlpox Viruses carrying multiple vaccine antigens and immunomodulatory Molecules. Biotechniques 37(1): 104–11. DOI: https://doi.org/10.2144/04371RR02

4. Chakrabarti S, Sisler J R and Moss B. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094–97. DOI: https://doi.org/10.2144/97236st07

5. Chen H Y, Cui P, Cui B A, Li H P, Jiao X Q, Zheng L L, Cheng G and Chao A J. 2011. Immune responses of chickens inoculated with a recombinant fowlpox vaccine co-expressing glycoprotein B of infectious laryngo-tracheitis virus and chicken IL-18. FEMS Immunology and Medical Microbiology 63: 289–95. DOI: https://doi.org/10.1111/j.1574-695X.2011.00850.x

6. de Felipe F P. 2002. Polycistronic viral vectors. Current Gene Therapy 2: 355–78. DOI: https://doi.org/10.2174/1566523023347742

7. de Felipe F P. 2004. Skipping the co-expression problem: The new 2A “CHYSEL” technology. Genetic Vaccines Therapy 2: 13. DOI: https://doi.org/10.1186/1479-0556-2-13

8. de Felipe P, Luke G A, Hughes L E, Gani D, Halpin C and Ryan M D. 2006. Eunum pluribus: Multiple proteins from a selfprocessing polyprotein. Trends in Biotechnology 24: 68–75. DOI: https://doi.org/10.1016/j.tibtech.2005.12.006

9. Donnelly M L L, Hughes L E, Luke G, Mendoza H, Dam E, Gani D and Ryan M D. 2001. The ‘cleavage’ activities of foot-andmouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’sequences. Journal of General Virology 82: 1027–41. DOI: https://doi.org/10.1099/0022-1317-82-5-1027

10. Du S, Liu C, Zhu Y, Wang Y, Ren D, Wang M, Tan P, Li X, Tian M, Zhang Y and Li J. 2015. Construction and characterization of novel fowlpox virus shuttle vectors. Virus Research 197: 59–66. DOI: https://doi.org/10.1016/j.virusres.2014.12.015

11. Emerman M and Temin H M. 1984. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39: 459–67. DOI: https://doi.org/10.1016/0092-8674(84)90453-7

12. Freshney R I. 2000. Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications. (4th Ed.). pp. 181– 184. Wiley-Liss, New York.

13. Ibrahimi A, Velde G V, Reumers V, Toelen J, Thiry I, Vandeputte C, Vets S, Deroose C, Bormans G, Baekelandt V and Debyser Z. 2009. Highly efficient multi-cistronic lentiviral vectors with peptide 2A sequences. Human Gene Therapy 20: 845–60. DOI: https://doi.org/10.1089/hum.2008.188

14. Kim J H, Lee S R, Li L H, Park H J, Park J H, Lee K Y, Kim M K, Shin B A and Choi S Y. 2011. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6: e18556. DOI: https://doi.org/10.1371/journal.pone.0018556

15. Kirubaharan J J and Palaniswami K S. 2003. Final report of the ICAR scheme on preparation and standardization of oral pellet vaccine against Newcastle disease.

16. Kumar S and Boyle D B. 1990. A Poxvirus bidirectional promoter element with early/late and late functions. Virology 179: 151– 58. DOI: https://doi.org/10.1016/0042-6822(90)90284-X

17. Lewis J E, Brameld J M, Hill P, Barrett P, Ebling F J P and Jethwa P H. 2015. The use of a viral 2A sequence for the simultaneous over-expression of both the vgf gene and enhanced green fluorescent protein (eGFP) in vitro and in vivo. Journal of Neuroscience Methods 256: 22–29. DOI: https://doi.org/10.1016/j.jneumeth.2015.08.013

18. Liu Z, Chen O, Wall J B, Zheng M, Zhou Y, Wang L, Vaseghi H R, Qian L and Liu J. 2017. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Scientific Reports 7(1): 2193. DOI: https://doi.org/10.1038/s41598-017-02460-2

19. McGinnes LW, Pantua H, Reitter J and Morisson T. 2006. Newcastle disease virus: Propagation, quantification, and storage. Current Protocols in Microbiology 15: 15F 12. DOI: https://doi.org/10.1002/9780471729259.mc15f02s01

20. Moss B and Earl P. 2001. Overview of the vaccinia virus expression system. Current Protocols in Molecular Biology 3: 1–5. DOI: https://doi.org/10.1002/0471142727.mb1615s60

21. Panda A, Huang Z, Elankumaran S, Rockemann D D and Samal S K. 2004. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microbial Pathogenesis 36: 1– 10. DOI: https://doi.org/10.1016/j.micpath.2003.07.003

22. Paoletti E. 1996. Applications of Pox virus vectors to vaccination: An update. Proceedings of the National Academy of Sciences United States of America 93: 11349–353. DOI: https://doi.org/10.1073/pnas.93.21.11349

23. Ryan M D and Drew J. 1994. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO Journal 13: 928–33. DOI: https://doi.org/10.1002/j.1460-2075.1994.tb06337.x

24. Samal S K. 2011. The Biology of Paramyxoviruses. Caister Academic Press, USA. Sambrook J and Russell D W. 2001. Molecular Cloning: A Laboratory Manual. (3rd Ed.). Cold Spring Habour Laboratory Press, New York.

25. Skinner M A, Laidlaw S M, Eldaghayes I, Kaiser P and Cottingham M G. 2005. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Review of Vaccines 4: 63–76. DOI: https://doi.org/10.1586/14760584.4.1.63

26. Szymczak A L, Workman C J, Wang Y, Vignali K M, Dilioglou S, Vanin E F and Vignali D A. 2004. Addendum: Correction of multi-gene deficiency in vivo using a single “self-cleaving” 2A peptide-based retroviral vector. Nature Biotechnology 22: 1590. DOI: https://doi.org/10.1038/nbt1204-1590b

27. Szymczak A L and Vignali D A. 2005. Development of 2A peptidebased strategies in the design of multicistronic vectors. Expert Opinion on Biological Therapy 5: 627–38. DOI: https://doi.org/10.1517/14712598.5.5.627

28. Szymczak A L, Vignali K M and Vignali D A A. 2012. Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harbour Protocols 7: 199–204. DOI: https://doi.org/10.1101/pdb.ip067876

29. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth B C, Remm M and Rozen S G. 2012. Primer3-New Capabilities and Interfaces. Nucleic Acids Research 40: 1–12. DOI: https://doi.org/10.1093/nar/gks596